| abstract |
Triazolyl compounds of formula (I) wherein A is a 5-membered heterocyclic moiety; B is C6-14aryl or C5-14heteroaryl; L is SO2NRa, where Ra is H, C1-4alkyl or C1-4haloalkyl; R1 is C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C3-14carbocyclyl or C3-14heterocyclyl, each optionally substituted with 1-5 substituents selected from halo, ORb, SRb, NRbRc, NO, =O, CN, C1-4acyl, C1-6alkyl, C1-6haloalkyl, C3 8cycloalkyl, C(O)Rb and C(O)ORb; R2 is H, halo, C1-4alkyl or C1-4haloalkyl; R3 is H, C1 6alkyl, C1-6haloalkyl, C3-8cycloalkyl or C3-8heterocycloalkyl; R4 is H, halo, OR5, SR5, NR5R6, NO, =O, CN, acyl, C(O)ORb, C(O)NRbRc, C1-6alkyl, C3-14carbocyclyl or C3 14heterocyclyl; R5 and R6 are H, C(O)Rb, C1-4alkyl, C1-4haloalkyl, C3-8carbocyclyl or C3 8heterocyclyl; Rb and Rc are H, C1-4alkyl, C1-4haloalkyl, C1-4acyl, C3-7cycloalkyl or C3 7halocycloalkyl; m is 0-3 and n is 0-2; may be useful as inhibitors of Raf kinases, e.g. B Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example cancer, including lymphoma, leukemia and melanoma, and immunological diseases. |